Review of the Revised Geneva Score
Evidence to Action: Official Journal of MDCalc · 01.05.2026 · 022026 (01)
DOI: 10.65357/001c.161603 ↗Kurz gefasst
Fachartikel in der Zeitschrift Evidence to Action: Official Journal of MDCalc, online erschienen am 01.05.2026. Verfasst von Riddhi Desai.
Abstract (Originalsprache)
The Revised Geneva Score was derived to provide a completely objective clinical decision rule for suspected PE. In the derivation study (Le Gal et al., 2006), the score stratified patients into three probability groups: low (8% prevalence), intermediate (28%), and high (74%). The revised Geneva score is a validated clinical prediction rule for estimating the pre-test probability of pulmonary embolism (PE) in patients with suspected PE
Zitieren
APA
Desai, R. (2026). Review of the Revised Geneva Score. Evidence to Action: Official Journal of MDCalc, 022026(01). https://doi.org/10.65357/001c.161603
Vancouver
Desai R. Review of the Revised Geneva Score. Evidence to Action: Official Journal of MDCalc. 2026;022026(01). doi:10.65357/001c.161603
BibTeX
@article{Desai2026,
author = {Desai, Riddhi},
title = {Review of the Revised Geneva Score},
journal = {Evidence to Action: Official Journal of MDCalc},
year = {2026},
volume = {022026},
number = {01},
doi = {10.65357/001c.161603}
}
EUVIMED